Comparative Pharmacology
Head-to-head clinical analysis: MECLAN versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLAN versus TETRAMED.
MECLAN vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic